AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management
Number of subjects: 273
Study 9422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of the endometrium
Number of subjects: 273
Study 9422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical resection of the endometrium (chosen or randomised)
Number of subjects: 273
Study 9422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (chosen)
Number of subjects: 273
Study 8426038 — intervention group
Group type: EXPERIMENTAL
Intervention: Social service intervention
Number of subjects: 0
Study 8426038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 3391053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Rocephin)/gentamicin
Number of subjects: 49
Study 3391053 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin/gentamicin
Number of subjects: 49
Study 30753672 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss (8-week intervention)
Number of subjects: 77
Study 28116801 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ezetimibe 10 mg daily
Number of subjects: 50
Study 28116801 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 25957549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendisulfur(®) (group T)
Number of subjects: 0
Study 25957549 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 0
Study 23994369 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) at 500 mg/kg
Number of subjects: 0
Study 23994369 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol at 500 mg/kg
Number of subjects: 0
Study 21489570 — intervention group
Group type: EXPERIMENTAL
Intervention: Almonds (28 g) consumed with a standardized meal
Number of subjects: 19
Study 21489570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic almond ingestion (1 serving 5 d/wk for 12 weeks)
Number of subjects: 19
Study 19670137 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 1920
Study 19670137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1920
Study 21333560 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) without saphenofemoral junction ligation (SFL)
Number of subjects: 30
Study 21333560 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA) with saphenofemoral junction ligation (SFL)
Number of subjects: 30
Study 21333560 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA) without SFL
Number of subjects: 30
Study 21333560 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA) with SFL
Number of subjects: 30
Study 21333560 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 15716167 — intervention group
Group type: COMPARATOR
Intervention: NoGo-P3 latency in PD group
Number of subjects: 13
Study 15716167 — intervention group
Group type: COMPARATOR
Intervention: NoGo-P3 amplitude in PD group
Number of subjects: 13
Study 15716167 — intervention group
Group type: COMPARATOR
Intervention: NoGo-N2 amplitude in PD group
Number of subjects: 13
Study 15716167 — intervention group
Group type: COMPARATOR
Intervention: Omission and commission errors during ERP task in PD group
Number of subjects: 13
Study 15716167 — intervention group
Group type: COMPARATOR
Intervention: Cognitive function tests (WCST and VFT) in PD group
Number of subjects: 13
Study 15716167 — intervention group
Group type: EXPERIMENTAL
Intervention: NoGo-P3 latency correlation
Number of subjects: 13
Study 15716167 — intervention group
Group type: EXPERIMENTAL
Intervention: NoGo-P3 amplitude correlation
Number of subjects: 13
Study 11793403 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz electric and magnetic field at 100 V/m and 6 microT (EMF sensitive)
Number of subjects: 63
Study 11793403 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (field off)
Number of subjects: 63
Study 11793403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed (field on)
Number of subjects: 63
Study 9721057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropped posture (DP)
Number of subjects: 9
Study 9721057 — intervention group
Group type: COMPARATOR
Intervention: Upright posture (UP)
Number of subjects: 9
Study 9721057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aero posture (AP)
Number of subjects: 9
Study 7648909 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary blood glucose test
Number of subjects: 220
Study 2667606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (GVG)
Number of subjects: 89
Study 405624 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 47
Study 405624 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 47
Study 11768838 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 6 mg
Number of subjects: 123
Study 11768838 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 10 mg
Number of subjects: 123
Study 11768838 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 2 mg
Number of subjects: 123
Study 11768838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 29688615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Pfizer
Number of subjects: 157
Study 29688615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg subcutaneous injection via prefilled syringe (PFS) using drug substance manufactured by Boehringer Ingelheim Pharma
Number of subjects: 157
Study 29688615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bococizumab 150 mg subcutaneous injection via prefilled pen using drug substance manufactured by Pfizer
Number of subjects: 157
Study 29688615 — intervention group
Group type: COMPARATOR
Intervention: All treatments (PFS by Pfizer, PFS by Boehringer Ingelheim, prefilled pen by Pfizer)
Number of subjects: 157
Study 29449189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (radiotherapy plus chemotherapy consisting of two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Number of subjects: 660
Study 29449189 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (48.6 Gy in 1.8 Gy fractions given on 5 days per week)
Number of subjects: 660
Study 29449189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 660
Study 29449189 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 660
Study 25808454 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 94
Study 25808454 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 94
Study 25808454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 94
Study 24220749 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg administered 1 h preoperatively
Number of subjects: 53
Study 24220749 — intervention group
Group type: COMPARATOR
Intervention: Placebo 200 mg administered 1 h preoperatively
Number of subjects: 53
Study 23023808 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus group
Number of subjects: 10
Study 23023808 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 21162930 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Hirayama disease
Number of subjects: 123
Study 21162930 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 123
Study 17434845 — intervention group
Group type: EXPERIMENTAL
Intervention: FOTO treatment schedule (5 days on, 2 days off)
Number of subjects: 30
Study 17434845 — intervention group
Group type: EXPERIMENTAL
Intervention: FOTO treatment schedule with efavirenz-based regimens
Number of subjects: 30
Study 17434845 — intervention group
Group type: EXPERIMENTAL
Intervention: FOTO treatment schedule
Number of subjects: 30
Study 15154088 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH treatment (n=24)
Number of subjects: 44
Study 15154088 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treated, n=20)
Number of subjects: 44
Study 12243815 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) by protracted venous infusion
Number of subjects: 656
Study 12243815 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) by bolus
Number of subjects: 656
Study 12243815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior resection
Number of subjects: 656
Study 12243815 — intervention group
Group type: COMPARATOR
Intervention: Abdominoperineal resection
Number of subjects: 656
Study 7808895 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal perception scale (TS) during exposure to cold air at 8 degrees, 12 degrees, and 27 degrees C for 120 min.
Number of subjects: 8
Study 7808895 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal perception scale (TS)
Number of subjects: 8
Study 2803403 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 13
Study 2803403 — intervention group
Group type: COMPARATOR
Intervention: Placebo or four inhalant anti-asthmatic drugs
Number of subjects: 13
Study 1125119 — intervention group
Group type: EXPERIMENTAL
Intervention: QX-572 (8 mg/kg body weight intravenously over 30 minutes)
Number of subjects: 67
Study 1125119 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 67
Study 1125119 — intervention group
Group type: EXPERIMENTAL
Intervention: QX-572
Number of subjects: 67
Study 30906714 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium partial ossicular replacement prosthesis (PORP)
Number of subjects: 32
Study 30906714 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium total ossicular replacement prosthesis (TORP)
Number of subjects: 32
Study 30906714 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cartilage short columella ossiculoplasty (SCC)
Number of subjects: 32
Study 30906714 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cartilage long columella ossiculoplasty (LCC)
Number of subjects: 32
Study 28051877 — intervention group
Group type: EXPERIMENTAL
Intervention: Adventures aboard the S.S. GRIN (computer-based game)
Number of subjects: 69
Study 28051877 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 69
Study 26304941 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1 mg followed by 0.5 mg 1 hour later)
Number of subjects: 83
Study 26304941 — intervention group
Group type: COMPARATOR
Intervention: No colchicine (control)
Number of subjects: 83
Study 23538664 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 gram monosodium glutamate (MSG)
Number of subjects: 60
Study 23538664 — intervention group
Group type: COMPARATOR
Intervention: 0.5 gram iodized salt
Number of subjects: 60
Study 23538664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (MSG and iodized salt)
Number of subjects: 60
Study 20951830 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural flour baked goods (NFBG) (80,127 ppm gluten; n = 6)
Number of subjects: 13
Study 20951830 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed flour baked goods (S1BG) (2480 ppm residual gluten; n = 2)
Number of subjects: 13
Study 20951830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully hydrolyzed baked goods (S2BG) (8 ppm residual gluten; n = 5)
Number of subjects: 13
Study 18449849 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 217
Study 18449849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 16571156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral (MVM) and zinc (Zn) supplementation
Number of subjects: 499
Study 16571156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral (MVM)
Number of subjects: 499
Study 16571156 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn)
Number of subjects: 499
Study 16571156 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral (MVM) and zinc (Zn) combined
Number of subjects: 499
Study 16571156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both MVM and Zn)
Number of subjects: 499
Study 12421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual identity primes (silent reading or semantic processing)
Number of subjects: 0
Study 12421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory identity primes (generating an associate or a rhyme)
Number of subjects: 0
Study 12421053 — intervention group
Group type: COMPARATOR
Intervention: Nonwords
Number of subjects: 0
Study 12421053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency words presented in the lexical decision task
Number of subjects: 0
Study 10341163 — intervention group
Group type: EXPERIMENTAL
Intervention: D-tagatose (29 g)
Number of subjects: 29
Study 10341163 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (29 g)
Number of subjects: 29
Study 7627294 — intervention group
Group type: EXPERIMENTAL
Intervention: No-rinse cleanser with moisture barrier
Number of subjects: 10
Study 7627294 — intervention group
Group type: EXPERIMENTAL
Intervention: No-rinse cleanser without moisture barrier
Number of subjects: 10
Study 7627294 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water with moisture barrier
Number of subjects: 10
Study 7627294 — intervention group
Group type: COMPARATOR
Intervention: Soap and water without moisture barrier
Number of subjects: 10
Study 2390547 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 146
Study 2390547 — intervention group
Group type: COMPARATOR
Intervention: Regional anaesthesia
Number of subjects: 146
Study 6793298 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg NET + 35 microgram EE
Number of subjects: 4
Study 6793298 — intervention group
Group type: EXPERIMENTAL
Intervention: Products containing EDA and NET
Number of subjects: 4
Study 6793298 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐containing preparation
Number of subjects: 4
Study 6793298 — intervention group
Group type: EXPERIMENTAL
Intervention: NET or EDA preparations
Number of subjects: 4
Study 6793298 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG preparation
Number of subjects: 4
Study 30855417 — intervention group
Group type: EXPERIMENTAL
Intervention: Histogram analysis of gray-scale ultrasound images in CHB patients
Number of subjects: 52
Study 30855417 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 52
Study 30855417 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups of CHB patients according to HAI stage
Number of subjects: 52
Study 30855417 — intervention group
Group type: EXPERIMENTAL
Intervention: First percentile values in CHB patients
Number of subjects: 52
Study 29674252 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel assistance (16.0%)
Number of subjects: 119
Study 29674252 — intervention group
Group type: COMPARATOR
Intervention: Distance from study site
Number of subjects: 119
Study 29674252 — intervention group
Group type: COMPARATOR
Intervention: Marital status of primary caregiver
Number of subjects: 119
Study 29674252 — intervention group
Group type: COMPARATOR
Intervention: Socioeconomic status (SES) variables
Number of subjects: 119
Study 28683560 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week dance intervention (BAILAMOS)
Number of subjects: 21
Study 28683560 — intervention group
Group type: COMPARATOR
Intervention: wait-list control
Number of subjects: 21
Study 26316098 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-guided technique
Number of subjects: 160
Study 26316098 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 160
Study 23945981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 75
Study 20336327 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) during intravenous chemotherapy
Number of subjects: 137
Study 20336327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR during intravenous chemotherapy)
Number of subjects: 137
Study 18292082 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel (AnGEL)
Number of subjects: 177
Study 18292082 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine and prilocaine in a 1:1 emulsion (EMLA)
Number of subjects: 177
Study 16542370 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily for 14 days
Number of subjects: 30
Study 16542370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 12669261 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated 30-min individual time-trial (ITT30) at self-selected intensity
Number of subjects: 12
Study 12669261 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected intensity during ITT30
Number of subjects: 12
Study 12669261 — intervention group
Group type: EXPERIMENTAL
Intervention: ITT30 performance test
Number of subjects: 12
Study 10634372 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy (telecobalt) in 20 fractions of 1 Gray (Gy) weekly over 20 weeks (group A)
Number of subjects: 36
Study 10634372 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy (telecobalt) in 10 fractions of 1 Gy daily over 2 weeks (group B)
Number of subjects: 36
Study 10634372 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy (telecobalt) in 10 fractions of 2 Gy daily over 2 weeks (group C)
Number of subjects: 36
Study 10634372 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A vs. group C
Number of subjects: 36
Study 10634372 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A vs. group B
Number of subjects: 36
Study 10634372 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group B vs. group C
Number of subjects: 36
Study 9150778 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane-nitrous oxide-oxygen
Number of subjects: 12
Study 9150778 — intervention group
Group type: COMPARATOR
Intervention: isoflurane-air-oxygen
Number of subjects: 12
Study 7960186 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment preceding gamete recovery
Number of subjects: 391
Study 7960186 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of peroxidase-positive cells (> 6 x 10(6)/ml)
Number of subjects: 391
Study 7960186 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of microorganisms in semen
Number of subjects: 391
Study 7960186 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased presence of peroxidase-negative cells
Number of subjects: 391
Study 3296741 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone-furosemide combination
Number of subjects: 9
Study 3296741 — intervention group
Group type: COMPARATOR
Intervention: Thiazide-furosemide combination
Number of subjects: 9
Study 29089415 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural heparin (HEP+)
Number of subjects: 173
Study 29089415 — intervention group
Group type: EXPERIMENTAL
Intervention: TICI 2b-3 reperfusion
Number of subjects: 173
Study 29089415 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent retriever use
Number of subjects: 173
Study 29089415 — intervention group
Group type: COMPARATOR
Intervention: Intubation
Number of subjects: 173
Study 29089415 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 173
Study 29089415 — intervention group
Group type: COMPARATOR
Intervention: NIHSS
Number of subjects: 173
Study 29089415 — intervention group
Group type: COMPARATOR
Intervention: Time from symptom onset to puncture
Number of subjects: 173
Study 29089415 — intervention group
Group type: COMPARATOR
Intervention: Heart failure
Number of subjects: 173
Study 25968885 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 615
Study 25968885 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 615
Study 26281144 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib intervention for late ABMR
Number of subjects: 714
Study 26281144 — intervention group
Group type: EXPERIMENTAL
Intervention: DSA+ABMR+ patients
Number of subjects: 714
Study 23493382 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP visit‐to‐visit variability (SBV)
Number of subjects: 908
Study 20056180 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei conjugate (25 microg, injected IM twice, 6 weeks apart)
Number of subjects: 2799
Study 20056180 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a conjugate (25 microg, injected IM twice, 6 weeks apart)
Number of subjects: 2799
Study 20056180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2799
Study 18208904 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13
Study 18208904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17074243 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fiber dressing (group T)
Number of subjects: 277
Study 17074243 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine gauze (group C)
Number of subjects: 277
Study 12196364 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC chemotherapy (high-dose cyclophosphamide, thiotepa, carboplatin)
Number of subjects: 152
Study 12196364 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC chemotherapy (standard-dose fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 152
Study 12196364 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (conventional cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 152
Study 12196364 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated stage I breast cancer patients)
Number of subjects: 152
Study 9817289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spitzer Uniscale (UNISCALE)
Number of subjects: 128
Study 9817289 — intervention group
Group type: COMPARATOR
Intervention: Functional Living Index‐Cancer (FLIC)
Number of subjects: 128
Study 9817289 — intervention group
Group type: COMPARATOR
Intervention: Spitzer QOL index (QLI)
Number of subjects: 128
Study 9817289 — intervention group
Group type: COMPARATOR
Intervention: Picture-face scale (PICT)
Number of subjects: 128